Furthermore, therapies aimed at reducing CCL7 levels or blocking its receptor could potentially mitigate the inflammatory and insulin-resistant aspects of PCOS, paving the way for novel treatment strategies. This evidence concerns the gene INS and polycystic ovary syndrome.